Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2013
Bipolar disorder: assessment and management (CG185)Product type:GuidanceProgramme:Clinical guidelineLast updated: 21 December 2023Published: 24 September 2014
Bipolar disorder: assessment and management (extraordinary review)Status:In developmentProgramme:NICE guidelineExpected publication date: TBC
Bipolar disorder in adults (QS95)Product type:Quality standardLast updated: 18 February 2016Published: 23 July 2015
Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)Product type:Quality standardPublished: 15 October 2015
Coexisting severe mental illness and substance misuse (QS188)Product type:Quality standardPublished: 20 August 2019
Coexisting severe mental illness and substance misuse: community health and social care services (NG58)Product type:GuidanceProgramme:NICE guidelinePublished: 30 November 2016
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guidance on the use of electroconvulsive therapy (TA59)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 October 2009Published: 26 April 2003
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 May 2013